Retina Research

Retina Research

Conbercept IVT Injection for Wet Age-related Macular Degeneration

Chengdu Kanghong Biotech Panda KHB-1802

A Phase III study to evaluate the safety and efficacy of intravitreal (IVT) injections of conbercept versus aflibercept in subjects with neovascular (wet) age-related macular degeneration (wAMD).

Both conbercept and aflibercept inhibit a protein (VEGF) that promotes the growth of the abnormal blood vessels characteristic of wAMD. Aflibercept is the active ingredient in Eylea, a drug that has already received market approval. Conbercept is thought to bind more specifically to VEGF, reducing the dosage required, and also has a longer half-life than other available treatments.

  • Subjects age ≥ 50 years
  • 1140 subjects total
  • Study duration: 92 weeks
  • Recruiting subjects who have never received treatment for wAMD

Those that qualify may receive study-related care from a board-certified physician at no cost, receive compensation for time and travel, and have access to potential new medication.

Contact Retina Associates at 630.571.1501 or to learn more about Retina Research.

Visit our Patient Resources page to learn how we help.